CATALYSTEM Primary Hip System Makes its OR Debut

Smith+Nephew is reporting promising surgeon feedback from the first completed cases using its new CATALYSTEM Primary Hip System.

Designed to address the evolving demands of primary hip surgery— including the increased adoption of anterior approach procedures—the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.¹  The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.²
 
The CATALYSTEM Primary Hip System made its O.R. debut last week in the United States. “Smith+Nephew’s new CATALYSTEM Primary Hip System with RI.HIP NAVIGATION represents the beginning of a new era combining advanced technology and patient personalization that will, without doubt, enhance patient outcomes,” said Dr. Thorsten Seyler of Duke University.
 
The CATALYSTEM Primary Hip System also uses proprietary, patent-pending, ACCUBROACH Technology that delivers proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating.^3,4
 
“The instruments were exceptionally user-friendly and ideal for the direct anterior approach,” commented George Haidukewych M.D., of Orlando Health in Orlando, Fla. “The broaches showed a significant improvement in performance, offering superior cutting and a more precise feel for rotational stability. In comparison to other implants I’ve used in recent years, these stand out as markedly better. Overall A-plus…it could not have gone better.”
 
Dr. Ran Schwarzkopf, Orthopedic Adult Hip and Knee Reconstruction Surgeon at NYU Langone Health, added, “The case went smoothly and exceeded all my expectations. It’s the best anatomically fitting stem I’ve ever seen—it fit the patient’s anatomy perfectly. The advantage of the broaches giving exact stem-to-broach positioning is unmatched in the industry.”
 
Smith+Nephew is an 18,000 employee-strong portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. It has three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in Hull, United Kingdom, in 1856, the company now operates in more than 100 countries, and generated $5.5 billion in annual sales last year. Smith+Nephew is a constituent of the FTSE100. 

References
¹ Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
² Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report.  CSD.REC.24.001
³ Smith + Nephew 2024. Cadaveric study of the repeatability of CATALYSTEM broach and femoral stem seating level. Internal Report. 10144794
⁴ Smith + Nephew 2024. CATALYSTEM Accubroach Femur to Bone Interaction Design Rationale. Internal Report. 10142827